Skip to main content
TipRanks
Go Ultimate75% OFF

Medrx Co., Ltd. (4586) AI Stock Analysis

0 Followers
JP:4586

Medrx Co., Ltd.

(TSE/TYO:4586)

Select Model
Rating:41Neutral
Price Target:JPY 48.00â–²(2.13% Upside)
Action:upgraded
Date:11/18/26

The overall score of 41 reflects a high-risk profile. The most significant factor is the company's severe unprofitability and ongoing cash burn, which heavily weigh on financial performance. The strong, debt-free balance sheet provides some stability but cannot compensate for the lack of revenue growth and earnings. Technical trends are bearish, with the stock trading well below its moving averages, and the negative P/E ratio offers no valuation support. The company's equity cushion is the primary positive, but a turnaround in operations is critical for any sustained improvement.

Positive Factors
Strong Gross MarginsThe sustained 85–90% gross-margin range indicates that the company’s products can retain substantial value after direct costs. If revenue expands through additional approvals or commercialization, this margin structure could provide operating leverage, although fixed expenses must first be covered.
Negative Factors
Persistent Deep LossesPersistent operating and net losses show that the current revenue base is insufficient to support the company’s expense structure. The sharp deterioration in 2025 net margin indicates that stronger gross profit has not yet translated into sustainable earnings, limiting internal funding capacity.

Medrx Co., Ltd. (4586) vs. iShares MSCI Japan ETF (EWJ)

-80%-60%-40%-20%0%20%40%JP:4586-59.48%EWJ+15.53%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
JPY 5.49B
Dividend Yield
―
Average Volume (3M)
1.06M
Price to Earnings (P/E)
-3.6
Beta (1Y)
1.41
Revenue Growth
-81.42%
EPS Growth
36.56%
Country
Japan
Employees
21
Sector
Healthcare
Sector Strength
51
Industry
Drug Manufacturers - Specialty & Generic

Medrx Co., Ltd. Business Overview & Revenue Model

Company Description

Established in 2002 and headquartered in Higashikagawa, Japan, MedRx Co., Ltd is a pharmaceutical firm focused on developing drug formulations. The company primarily provides pharmaceutical products in Japan that leverage transdermal absorption syste...

How the Company Makes Money

Medrx primarily makes money by monetizing its transdermal drug delivery technologies and related pharmaceutical products. Key revenue streams typically include: (1) licensing/out-licensing of developed transdermal formulations or drug candidates to p...

Medrx Co., Ltd. Financial Statement Overview

Summary

Financial performance is severely constrained by deep unprofitability and high cash burn. The income statement shows a net loss margin of -732% on declining revenue, and cash flow from operations is deeply negative. The only mitigating factor is a strong, debt-free balance sheet with ample equity, which prevents a lower score but cannot offset the fundamental earnings weakness.

Income Statement

15Very Negative

Balance Sheet

80Positive

Cash Flow

20Very Negative
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue121.00M128.08M257.92M29.53M59.48M8.35M
Gross Profit109.78M113.01M219.19M-18.43M10.45M-54.25M
EBITDA-868.59M-928.13M-754.62M-888.00M-1.05B-1.00B
Net Income-858.85M-937.37M-806.76M-932.90M-1.11B-1.06B
Balance Sheet
Total Assets1.74B2.16B2.27B2.05B1.40B2.11B
Cash, Cash Equivalents and Short-Term Investments1.14B1.75B1.98B1.72B994.02M1.70B
Total Debt000000
Total Liabilities149.79M108.54M107.00M127.52M185.56M153.10M
Stockholders Equity1.59B2.05B2.17B1.92B1.21B1.96B
Cash Flow
Free Cash Flow0-970.86M-803.00M-913.76M-1.08B-926.23M
Operating Cash Flow0-888.11M-803.00M-913.00M-1.07B-923.69M
Investing Cash Flow0-82.75M-3.15M-759.00K-1.96M-2.54M
Financing Cash Flow0745.09M1.07B1.64B356.31M815.91M

Medrx Co., Ltd. Technical Analysis

Technical Analysis SentimentNeutral
Last Price47.00

Price Trends

50DMA52.74Negative
100DMA57.11Negative
200DMA73.15Negative

Market Momentum

MACD-3.07Negative
RSI50.78Neutral
STOCH62.18Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4586, the sentiment is Neutral. The current price of 47.00 is above the 20-day moving average (MA) of 44.40, below the 50-day MA of 52.74, and below the 200-day MA of 73.15, indicating a neutral trend. The MACD of -3.07 indicates Negative momentum. The RSI at 50.78 is Neutral, neither overbought nor oversold. The STOCH value of 62.18 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for JP:4586.

Medrx Co., Ltd. Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

JP:4586 against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
JP:4582JP:458248NeutralJPY 7.16B-0.82――-30.58%6.93%
JP:4539JP:453947NeutralJPY 5.57B-11.41―3.24%0.31%-194.72%
JP:4883JP:488343NeutralJPY 3.73B-1.41―――25.34%
JP:4892JP:489242NeutralJPY 5.08B-6.53――214.65%22.18%
JP:4586JP:458641NeutralJPY 3.71B-3.58――-81.42%36.56%
JP:4597JP:459739UnderperformJPY 6.55B-7.89-53.06%―109.82%61.98%

* Healthcare Sector Average

Performance Comparison

-50%0%50%JP:4586JP:4597JP:4539JP:4582JP:4883JP:4892Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
JP:4586 and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
JP:4586Medrx Co., Ltd.47.00-75.00-61.48%
JP:4597Solasia Pharma KK24.00-7.00-22.58%
JP:4539Nippon Chemiphar Co., Ltd.1543.0068.974.68%
JP:4582Symbio Pharmaceuticals Limited71.00-33.00-31.73%
JP:4883Modalis Therapeutics Corporation31.00-36.00-53.73%
JP:4892Cyfuse Biomedical K.K.515.00-69.00-11.82%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 18, 2026